A Phase 2 interventional study of Placebo and Neurotropin in Complex Regional Pain Syndrome Type I and Complex Regional Pain Syndrome Type II, sponsored by National Institute of Nursing Research (NINR). Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-22.
Sponsored by National Institute of Nursing Research (NINR) · Phase 2, Interventional, and Treatment
This study will examine the effectiveness of the drug neurotropin in treating chronic pain after injury to a limb or a large nerve.
Two groups of patients will participate in this study: patients with complex regional pain syndrome type 1, or CRPS-I (also called reflex sympathetic dystrophy) and patients with complex regional pain syndrome type 2, or CRPS-II. CRPS-I is pain that develops after relatively minor injury to an arm or leg, but lasts much longer and is much more severe than would normally be expected. CRPS-II is pain resulting from injury to a large nerve. Candidates will have a history and physical examination, blood tests, and electrocardiogram. Participants will undergo the following tests and procedures:
Patients with CRPS I and II will receive an individualized regimen of physical therapy and standard treatment to control their pain. In addition, they will receive neurotropin or placebo tablets for 5 weeks, then no trial medicine for at least 1 week, and then the other trial drug for the next 5 weeks. That is, patients who took placebo the first 5 weeks will take neurotropin the second 5 weeks and vice versa. Neither the patients nor the doctors will know who received which drug during the two intervals until the study is over. Patients will complete questionnaires about their pain, quality of life, and ability to perform daily living activities. They will have various tests to measure pain (such as sensitivity to heat and cold, to an electric current, to a mild pin prick, etc.); to provide information about changes in their condition (such as tests of range of motion of joints and limb size); to measure blood circulation and sweating in the arm or leg (such as measurements of blood flow to the limb, skin temperature, and sweat production), and other procedures.
Patients with Reflex Sympathetic Dystrophy (RSD), re-named Complex Regional Pain Syndrome, type I (CRPS-I), have chronic, post-traumatic pain that spreads beyond the distribution of any single peripheral nerve without evidence of major peripheral nerve damage. A similar disorder, Causalgia, re-named CRPS-II, presents with clear evidence of nerve injury. No successful drug treatment exists for these disorders. Neurotropin is a non-protein extract of cutaneous tissue from rabbits inoculated with vaccinia virus. Neurotropin has been used extensively in Japan to treat RSD and other painful conditions; however, the drug has not undergone clinical therapeutic testing in the United States. This protocol is to carry out double-blind, placebo-controlled, crossover studies about clinical efficacy of Neurotropin for acute pain in dental outpatients and for chronic pain in outpatients with CRPS-I or II.
1,287 studies on the registry are indexed under Neuralgia; 256 are open to participants now.
This study's enrollment of 21 is below the median of 52 across 973 interventional studies indexed under Neuralgia.
Browse Neuralgia studies →National Institute of Nursing Research (NINR) is the lead sponsor of 48 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
CRPS patients are referred with a diagnosis of CRPS-I or CRPS-II in one limb only, based on pain (1) that is post-traumatic and spread beyond the region of the injury; (2) has persisted for more than 2 weeks; and (3) is associated with swelling, altered skin color or skin temperature, altered sweating, allodynia or hyperesthesia or limitation of active movement. Atrophic changes in skin, hair loss or nail changes, or disuse atrophy of skeletal muscle may be present.
Both sexes are to be studied.
All ethnic and racial groups can participate.
Patients must be willing to return to NIH for follow-up evaluation under this protocol.
EXCLUSION CRITERIA:
Pregnant and lactating women are excluded.
Based on the oral surgeon's postoperative diagnosis, any extraction which is classified as producing unusual surgical trauma will result in exclusion from the remainder of the study.
Dental subjects will also be excluded if they are not adequately sedated by midazolam alone and require intraoperative administration of an opioid drug such as fentanyl, administration of greater than 14.4 ml of local anesthetic (2% lidocaine with 1:100,000 epinephrine), or postoperative administration of a steroid for possible injury to the inferior alveolar nerve.
Patients referred with CRPS-I or CRPS II who have abnormal screening test results or who have non-traumatic disorders to which pain may be attributed (gout, malignancy, arthritis, etc.) will be excluded.
Any patients who have had ablative procedures for treatment of their neuropathic pain disorder will not be eligible for inclusion in this study.
Patients who have a positive HIV result will be excluded.
Subjects with obviously impaired mental capacity that precludes informed consent and ability to provide adequate self-ratings are to be excluded.
Double blind cross-over study: receive placebo for 5 weeks and then Neurotropin for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
Drug: Placebo · Drug: Neurotropin
Double blind cross-over study: receive Neurotropin for 5 weeks and then placebo for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
Drug: Placebo · Drug: Neurotropin
4 tabs b.i.d.
Also known as: Drug A
4 tabs b.i.d.
Also known as: Drug B
Visual Analogue Scale (VAS) of Pain Scores After Administration of Test Drugs (Placebo or Neurotropin )
Assessments of pain severity by the patient using a visual analogue scale ranging from 0 to 100 (mm), with 0 = no pain and 100 = maximal pain level. When it is difficult to recruit the patients, the interim analysis using these data is performed after completion of the study of first 16 patients (target number is 30). The data from 16 patients was analyzed while investigators were blinded to the treatment code (Drug A and B) provided by the NIH pharmacy. Only after the analysis was completed was the code unblinded. Placebo or Neurotropin" in place of "drug A or drug B.
Time frame: VAS of each patient is measured after each 5-week treatment interval with placebo or Neurotropin.
Numeric Rating Scale (NRS) of Pain Scores After Administration of Test Drugs (Neurotropin or Placebo)
Assessments of pain severity by the patient using a numeric rating scale ranging from 0 to 10 as a verbal response where 0 = no pain and 10 =maximal pain. When it is difficult to recruit the patients, the interim analysis using these data is performed after completion of the study of first 16 patients (target number is 30). The data from 16 patients was analyzed while the investigators are blinded to the treatment code (Drug A or B) provided by the NIH pharmacy. Only after the analysis was completed was the code unblinded. Placebo or Neurotropin" in place of "drug A or drug B.
Time frame: NRS of each patient is measured after each five-week treatment interval with placebo or Neurotropin.
McGill Pain Questionnaire (MPQ) of Scores After Administration of Test Drugs (Neurotropin or Placebo)
Assessments of pain severity by the patient using a McGill Pain Questionnaire which consists of 3 major classes of word descriptors-sensory, affective and evaluative - that are used by patients to specify subjective pain experience. Each word chosen from descriptor responses to 20 questions is given a value and the sum of the values of the responses provides a score which is an index of the pain severity with a minimum value of 20 and a maximal value of 78. When it is difficult to recruit the patients, the interim analysis using these data is performed after completion of the study of first 16 patients (target number is 30). The data from 16 patients was analyzed while investigators are blinded to the treatment code (drug A or B) provided by the NIH pharmacy. Only after the analysis was completed was the code unblinded. Placebo or Neurotropin" in place of "drug A or drug B.
Time frame: MPQ of each patient is measured after each five-week treatment interval with drug A or drug B.
Most patients are recruited by direct physician referral or through the Patient Recruitment and Public Liaison (PRPL) office. Potential subjects are determined to be qualified by screening at Clinical Center, NIH in the US.
| Milestone | Placebo First, Then Neurotropin | Neurotropin First, Then Placebo |
|---|---|---|
| Started | 11 | 10 |
| Completed | 10 | 10 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Placebo First, Then Neurotropin | Neurotropin First, Then Placebo |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
| Milestone | Placebo First, Then Neurotropin | Neurotropin First, Then Placebo |
|---|---|---|
| Started | 10 | 10 |
| Completed | 9 | 9 |
| Not completed | 1 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
Assessments of pain severity by the patient using a visual analogue scale ranging from 0 to 100 (mm), with 0 = no pain and 100 = maximal pain level. When it is difficult to recruit the patients, the interim analysis using these data is performed after completion of the study of first 16 patients (target number is 30). The data from 16 patients was analyzed while investigators were blinded to the treatment code (Drug A and B) provided by the NIH pharmacy. Only after the analysis was completed was the code unblinded. Placebo or Neurotropin" in place of "drug A or drug B.
| mm | VAS After Placebo Treatment First in G-1 | VAS After Neurotropin Treatment Second in G-1 | VAS After Neurotropin Treatment First in G-2 | VAS After Placebo Treatment Second in G-2 |
|---|---|---|---|---|
| Visual Analogue Scale (VAS) of Pain Scores After Administration of Test Drugs (Placebo or Neurotropin ) | 33.6 ± 11.1 | 38.3 ± 8.8 | 36.0 ± 7.6 | 31.1 ± 7.7 |
Assessments of pain severity by the patient using a numeric rating scale ranging from 0 to 10 as a verbal response where 0 = no pain and 10 =maximal pain. When it is difficult to recruit the patients, the interim analysis using these data is performed after completion of the study of first 16 patients (target number is 30). The data from 16 patients was analyzed while the investigators are blinded to the treatment code (Drug A or B) provided by the NIH pharmacy. Only after the analysis was completed was the code unblinded. Placebo or Neurotropin" in place of "drug A or drug B.
| units on a scale | NRS After Placebo Treatment First in G-1 | NRS After Neurotropin Treatment Second in G-1 | NRS After Neurotropin Treatment First in G-2 | NRS After Placebo Treatment Second in G-2 |
|---|---|---|---|---|
| Numeric Rating Scale (NRS) of Pain Scores After Administration of Test Drugs (Neurotropin or Placebo) | 3.0 ± 1.1 | 3.3 ± 0.9 | 4.0 ± 0.8 | 3.1 ± 0.8 |
Assessments of pain severity by the patient using a McGill Pain Questionnaire which consists of 3 major classes of word descriptors-sensory, affective and evaluative - that are used by patients to specify subjective pain experience. Each word chosen from descriptor responses to 20 questions is given a value and the sum of the values of the responses provides a score which is an index of the pain severity with a minimum value of 20 and a maximal value of 78. When it is difficult to recruit the patients, the interim analysis using these data is performed after completion of the study of first 16 patients (target number is 30). The data from 16 patients was analyzed while investigators are blinded to the treatment code (drug A or B) provided by the NIH pharmacy. Only after the analysis was completed was the code unblinded. Placebo or Neurotropin" in place of "drug A or drug B.
| units on a scale | MPQ After Placebo Treatment First in G-1 | MPQ After Neurotropin Treatment Second in G-1 | MPQ After Neurotropin Treatment First in G-2 | MPQ After Placebo Treatment Second in G-2 |
|---|---|---|---|---|
| McGill Pain Questionnaire (MPQ) of Scores After Administration of Test Drugs (Neurotropin or Placebo) | 22.4 ± 5.9 | 33.1 ± 4.0 | 25.4 ± 4.9 | 27.1 ± 5.7 |
Collected over Adverse event information will be collected during the treatments and 5 weeks after the completion of study.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo First, Then Neurotropin | — | 0/11 (0%) | 1/11 (9.1%) |
| Neurotropin First, Then Placebo | — | 0/10 (0%) | 0/10 (0%) |
| Event | Placebo First, Then Neurotropin | Neurotropin First, Then Placebo |
|---|---|---|
| worsening of painNervous system disorders | 1/11 | 0/10 |
Clinical evaluation includes blood chemistries (acute care, hepatic panel, and mineral panel) as well as measurements of pain (including allodynia, hyperalgesia, and hyperpathia), edema, autonomic dysfunction (altered skin color, temperature, or sudomotor activity) and extent of movement disorders.
| Age, Categorical(Participants) | Placebo First, Then Neurotropin | Neurotropin First, Then Placebo | Total |
|---|---|---|---|
| <=18 years | 2 | 0 | 2 |
| Between 18 and 65 years | 9 | 9 | 18 |
| >=65 years | 0 | 1 | 1 |
| Age, Continuous(years) | Placebo First, Then Neurotropin | Neurotropin First, Then Placebo | Total |
|---|---|---|---|
| Mean | 37.3 ± 13.2 | 46.5 ± 13.2 | 41.7 ± 13.7 |
| Sex: Female, Male(Participants) | Placebo First, Then Neurotropin | Neurotropin First, Then Placebo | Total |
|---|---|---|---|
| Female | 10 | 5 | 15 |
| Male | 1 | 5 | 6 |
| Region of Enrollment(participants) | Placebo First, Then Neurotropin | Neurotropin First, Then Placebo | Total |
|---|---|---|---|
| United States | 11 | 10 | 21 |
This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Nursing Research (NINR)